BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y, Mori M. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. Hepatol Commun 2021;5:334-48. [PMID: 33553979 DOI: 10.1002/hep4.1643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X, Shi S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer 2021;20:131. [PMID: 34635121 DOI: 10.1186/s12943-021-01428-1] [Reference Citation Analysis]
2 Wang Z, Peng Z, Liu Q, Guo Z, Menatola M, Su J, Li T, Ge Q, Wang P, Shen L, Jin R. Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma. Cancers (Basel) 2021;13:5175. [PMID: 34680324 DOI: 10.3390/cancers13205175] [Reference Citation Analysis]
3 Itoh S, Yoshizumi T, Kitamura Y, Yugawa K, Iseda N, Shimagaki T, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M. Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation. Hepatol Commun 2021;5:1278-89. [PMID: 34278175 DOI: 10.1002/hep4.1715] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Iseda N, Itoh S, Yoshizumi T, Tomiyama T, Morinaga A, Yugawa K, Shimokawa M, Shimagaki T, Wang H, Kurihara T, Kitamura Y, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M. Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status. Hepatol Commun 2021. [PMID: 34687175 DOI: 10.1002/hep4.1838] [Reference Citation Analysis]
5 Liang J, Li S, Li W, Rao W, Xu S, Meng H, Zhu F, Zhai D, Cui M, Xu D, Cai J, Zhang B. CMTM6, a potential immunotherapy target. J Cancer Res Clin Oncol 2021. [PMID: 34783871 DOI: 10.1007/s00432-021-03835-9] [Reference Citation Analysis]